• In early February 2026, FactSet Research Systems announced a beta release of its AI Doc Ingest tool for Cobalt and a new partnership to integrate Kepler Cheuvreux’s European Aftermarket Research into the FactSet platform, extending AI-enhanced coverage of more than 1,000 stocks across 34 sectors in EMEA.
• These moves highlight FactSet’s push to automate data-heavy workflows for private capital managers while deepening differentiated European equity research content, broadening how clients can use AI-driven insights across public and private markets.
• Next, we’ll examine how integrating Kepler Cheuvreux’s research into FactSet’s AI platform could influence the company’s longer-term investment narrative.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

FactSet Research Systems Investment Narrative Recap

To own FactSet, you need to believe its data and workflow platform can keep earning a meaningful share of financial institutions’ tech budgets, even as clients scrutinize costs and inflation driven price lifts fade. The Kepler Cheuvreux partnership and AI Doc Ingest beta look directionally helpful for strengthening content and automation, but do not fundamentally change the near term focus on stabilizing growth in pressured banking and asset management segments or the margin risk from rising technology spend.

Among the recent developments, the AI Doc Ingest beta for Cobalt is most closely tied to the core catalyst of expanding higher value, AI enabled workflows. It directly addresses one of FactSet’s key opportunities: using automation to improve productivity and offset higher cloud and software expenses that are weighing on margins. If it sees strong adoption, this type of product could help support the broader thesis that FactSet can grow ASV while keeping profitability resilient.

Yet, for all the promise of FactSet’s AI tools, investors should still watch how quickly these offerings really gain traction, because...

FactSet Research Systems' narrative projects $2.7 billion revenue and $730.7 million earnings by 2028. This requires 5.7% yearly revenue growth and about a $200 million earnings increase from $532.9 million today.

Uncover how FactSet Research Systems' forecasts yield a $319.00 fair value, a 65% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenue of about US$2.8 billion and earnings near US$726 million by 2028, which is much more upbeat than consensus. In light of the new Kepler Cheuvreux partnership and AI Doc Ingest launch, you may want to weigh that optimism against the risk that AI investments do not translate into the faster client adoption and margin lift those forecasts depend on.

Explore 5 other fair value estimates on FactSet Research Systems - why the stock might be worth just $276.99!

Build Your Own FactSet Research Systems Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your FactSet Research Systems research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free FactSet Research Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate FactSet Research Systems' overall financial health at a glance.

Ready For A Different Approach?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 28 elite penny stocks that balance risk and reward.
• Rare earth metals are the new gold rush. Find out which 32 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.